Chiesi completes European regulatory submissions for the transition of Fostair® (beclometasone / formoterol) and Trimbow® (beclometasone / formoterol / glycopyrronium) to a next-generation, carbon minimal, propellant

Key Highlights

- Regulatory submissions for next-generation propellant pMDIs (pressurised metered-dose inhalers) Fostair® (beclometasone / formoterol) and Trimbow® (beclometasone / formoterol / glycopyrronium) have been validated by Regulatory Agencies in Europe and assessments are now underway. [1-4]
- Chiesi's transition to HFA-152a*, a next-generation propellant classified as non-PFAS† and with low global warming potential (GWP), aims to reduce the carbon footprint of its pMDIs by up to 90%. [5-7]
- The transition supports Chiesi's ambition to reach Net Zero‡ across its full value chain by 2035. [8]

Manchester, UK – 3rd September 2026 – Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces the progression of its Carbon Minimal Inhaler (CMI) portfolio with the validation of European regulatory submissions for the transition of Fostair® (beclometasone / formoterol) and Trimbow® (beclometasone / formoterol / glycopyrronium) to a next-generation, low-GWP propellant. [1-4]

The validation of regulatory submissions for these products means the assessment processes have officially begun and marks a significant step towards Chiesi's transition to carbon minimal pMDIs. The transition supports the company's broader ambition to reduce the environmental impact of respiratory care while ensuring that patients maintain access to the device that is most suitable for them.

"At Chiesi, our focus is on delivering innovation that supports both patients and the planet - reducing environmental impact, while preserving choice and flexibility in treatment. By evolving our portfolio in this way, we're changing so patients don't have to." said Ralph Blom, General Manager, Chiesi UK and Ireland.

Many of Chiesi's pMDIs are transitioning to HFA-152a*, a next-generation propellant classified as non-PFAS† and with low-GWP, designed to reduce the products' carbon footprint by up to 90%, compared with its current pMDIs which are formulated with HFA-134a*. [5-7] Pharmacokinetic and safety studies

have demonstrated therapeutic equivalence and tolerability between the propellants, within Chiesi's pMDI portfolio. [9-13]

Chiesi's transition is focused on reducing the carbon footprint associated with pMDIs, a device which remains an important option in respiratory care. Transitioning its pMDIs to the next-generation propellant, HFA-152a*, supports the decarbonisation of respiratory care while helping to safeguard access and continuity of care over the long term. [5, 14-16]

Beclometasone / formoterol / glycopyrronium has been submitted under the EU centralised procedure to the European Medicines Agency, while beclometasone / formoterol is being managed through a coordinated multi-country regulatory procedure with BfArM – the German Federal Institute for Drugs and Medical Devices – acting as Reference Member State.

The UK regulator - the Medicines and Healthcare products Regulatory Agency (MHRA) - will validate these procedures once complete, with UK regulatory approval anticipated in the first half of 2027.

---

*HFA: hydrofluoroalkane.
†PFAS: per- and polyfluoroalkyl substances.

‡Net Zero Commitment

Chiesi plans to be the first pharmaceutical company to achieve Net Zero greenhouse gas emissions across its entire value chain by 2035, 15 years ahead of the European Climate Neutrality target. This commitment covers all emission scopes. Chiesi's targets were validated by the Science Based Targets initiative (SBTi) in April 2024.[8] The Group has consolidated its greenhouse gas inventory in line with ISO 14064 and the Greenhouse Gas (GHG) Protocol standards, with annual audits carried out by independent third parties.

The transition to the next-generation propellant is one of the most impactful actions in Chiesi's Net Zero roadmap, as inhaler propellants represent the single largest source of the Group's greenhouse gas emissions.

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By adopting the legal form of Benefit Corporation in Italy, the US, France, and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet verified standards for social and environmental business practices. The company aims to reach Net Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information, please visit www.chiesi.uk.com

******

Press info:

Yasmin Ghariani
Head of Communications, UK and Ireland
Tel: +44 755 720 5478
Email: y.ghariani@chiesi.com

References

[1] Electronic Medicines Compendium. Fostair pMDI 100/6, Summary of Product Characteristics.
[2] Electronic Medicines Compendium. Fostair pMDI 200/6, Summary of Product Characteristics.
[3] Electronic Medicines Compendium. Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms, Summary of Product Characteristics.
[4] Electronic Medicines Compendium. Trimbow pMDI 172 micrograms/5 micrograms/9 micrograms, Summary of Product Characteristics.
[5] Panigone S et al 2020, BMJ Open Respiratory Research: Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. Available at: https://doi.org/10.1136/bmjresp-2020-000571.
[6] EU ECHA Webinar: Restriction of per- and polyfluoroalkyl substances (PFAS) under REACH.
[7] OECD. Reconciling Terminology of the Universe of Per- and Polyfluoroalkyl Substances 2021. Available at: https://www.oecd.org/en/publications/reconciling-terminology-of-the-universe-of-per-and-polyfluoroalkyl-substances_e458e796-en.html.
[8] Chiesi UK. Sustainability Report 2024. Available at: https://www.chiesi.uk.com/sustainability/reports.

[9] Rony F et al 2024, Pulmonary Pharmacology & Therapeutics: Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler using a low global warming potential propellant. Available at: https://doi.org/10.1016/j.pupt.2024.102299.
[10] Almeida M et al 2026, Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0149291826001128.
[11] Salvadori M et al 2025, Pulmonary Pharmacology & Therapeutics: The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance. Available at: https://doi.org/10.1016/j.pupt.2025.102358.
[12] Singh D et al 2026, Respiratory Medicine: Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study. Available at: https://doi.org/10.1016/j.rmed.2026.108814.
[13] Rony F, Pittelli MG, Contursi C, Pacchetti I, Calabrò ER, Viganò LV, et al 2025, Pulmonary pharmacology & therapeutics: Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler. Available at: https://pubmed.ncbi.nlm.nih.gov/40090514/.
[14] Pernigotti D et al 2021, BMJ Open Respiratory Research: Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. Available at: https://doi.org/10.1136/bmjresp-2021-001071.
[15] Attar-Zadeh D et al 2021, Journal of Health Economics and Outcomes Research: Health-care Resource Requirements and Potential Financial Consequences of an Environmentally Driven Switch in Respiratory Inhaler Use in England. Available at: https://doi.org/10.36469/001c.26113.
[16] Usmani O et al 2022, Journal of Allergy Clinical Immunology Practice: Real-World Impact of Nonclinical Inhaler Regimen Switches on Asthma or COPD: A Systematic Review. Available at: https://doi.org/10.1016/j.jaip.2022.05.039.